These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

593 related articles for article (PubMed ID: 33421734)

  • 1. The neuropsychiatric manifestations of COVID-19: Interactions with psychiatric illness and pharmacological treatment.
    Jansen van Vuren E; Steyn SF; Brink CB; Möller M; Viljoen FP; Harvey BH
    Biomed Pharmacother; 2021 Mar; 135():111200. PubMed ID: 33421734
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Repurposing of Tetracyclines for COVID-19 Neurological and Neuropsychiatric Manifestations: A Valid Option to Control SARS-CoV-2-Associated Neuroinflammation?
    Chaves Filho AJM; Gonçalves F; Mottin M; Andrade CH; Fonseca SNS; Macedo DS
    J Neuroimmune Pharmacol; 2021 Jun; 16(2):213-218. PubMed ID: 33534108
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Repurposing of chlorpromazine in COVID-19 treatment: the reCoVery study].
    Plaze M; Attali D; Petit AC; Blatzer M; Simon-Loriere E; Vinckier F; Cachia A; Chrétien F; Gaillard R
    Encephale; 2020 Jun; 46(3S):S35-S39. PubMed ID: 32387014
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune Response Is Key to Genetic Mechanisms of SARS-CoV-2 Infection With Psychiatric Disorders Based on Differential Gene Expression Pattern Analysis.
    Xia J; Chen S; Li Y; Li H; Gan M; Wu J; Prohaska CC; Bai Y; Gao L; Gu L; Zhang D
    Front Immunol; 2022; 13():798538. PubMed ID: 35185890
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Psychopharmacology of COVID-19.
    Bilbul M; Paparone P; Kim AM; Mutalik S; Ernst CL
    Psychosomatics; 2020; 61(5):411-427. PubMed ID: 32425246
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Statins and SARS-CoV-2 disease: Current concepts and possible benefits.
    Minz MM; Bansal M; Kasliwal RR
    Diabetes Metab Syndr; 2020; 14(6):2063-2067. PubMed ID: 33120281
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SARS-CoV-2 multifaceted interaction with human host. Part I: What we have learnt and done so far, and the still unknown realities.
    Delcuve GP; Lakowski TM; Su RC; Beacon TH; Davie JR
    IUBMB Life; 2020 Nov; 72(11):2313-2330. PubMed ID: 32918855
    [TBL] [Abstract][Full Text] [Related]  

  • 8. COVID-19 and inflammatory bowel disease: A pathophysiological assessment.
    Yang C; Xiao SY
    Biomed Pharmacother; 2021 Mar; 135():111233. PubMed ID: 33433350
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neurological Consequences of SARS-CoV-2 Infection and Concurrence of Treatment-Induced Neuropsychiatric Adverse Events in COVID-19 Patients: Navigating the Uncharted.
    Borah P; Deb PK; Chandrasekaran B; Goyal M; Bansal M; Hussain S; Shinu P; Venugopala KN; Al-Shar'i NA; Deka S; Singh V
    Front Mol Biosci; 2021; 8():627723. PubMed ID: 33681293
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Challenges and management of neurological and psychiatric manifestations in SARS-CoV-2 (COVID-19) patients.
    Orsini A; Corsi M; Santangelo A; Riva A; Peroni D; Foiadelli T; Savasta S; Striano P
    Neurol Sci; 2020 Sep; 41(9):2353-2366. PubMed ID: 32767055
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Towards a pharmacochemical hypothesis of the prophylaxis of SARS-CoV-2 by psychoactive substances.
    Javelot H; Petrignet J; Addiego F; Briet J; Solis M; El-Hage W; Hingray C; Weiner L
    Med Hypotheses; 2020 Nov; 144():110025. PubMed ID: 33254478
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Informations on psychotropics and their adaptations for patients suffering from mental disorders in France during the SARS-CoV-2 epidemic].
    Javelot H; Llorca PM; Drapier D; Fakra E; Hingray C; Meyer G; Dizet S; Egron A; Straczek C; Roser M; Masson M; Gaillard R; Fossati P; Haffen E
    Encephale; 2020 Jun; 46(3S):S14-S34. PubMed ID: 32376004
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SARS-CoV-2 Psychiatric Sequelae: A Review of Neuroendocrine Mechanisms and Therapeutic Strategies.
    Hornick MG; Olson ME; Jadhav AL
    Int J Neuropsychopharmacol; 2022 Jan; 25(1):1-12. PubMed ID: 34648616
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Covid-19 and development of heart failure: mystery and truth.
    Onohuean H; Al-Kuraishy HM; Al-Gareeb AI; Qusti S; Alshammari EM; Batiha GE
    Naunyn Schmiedebergs Arch Pharmacol; 2021 Oct; 394(10):2013-2021. PubMed ID: 34480616
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: a systematic review and meta-analysis with comparison to the COVID-19 pandemic.
    Rogers JP; Chesney E; Oliver D; Pollak TA; McGuire P; Fusar-Poli P; Zandi MS; Lewis G; David AS
    Lancet Psychiatry; 2020 Jul; 7(7):611-627. PubMed ID: 32437679
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neurological and Neuropsychiatric Impacts of COVID-19 Pandemic.
    Roy D; Ghosh R; Dubey S; Dubey MJ; Benito-León J; Kanti Ray B
    Can J Neurol Sci; 2021 Jan; 48(1):9-24. PubMed ID: 32753076
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Psychiatric Manifestations of COVID-19: A Literature Review.
    Khatun A; Tamilanban T; Chitra V
    CNS Neurol Disord Drug Targets; 2023; 22(6):892-905. PubMed ID: 35786340
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comprehensive Landscape of Heparin Therapy for COVID-19.
    Shi C; Tingting W; Li JP; Sullivan MA; Wang C; Wang H; Deng B; Zhang Y
    Carbohydr Polym; 2021 Feb; 254():117232. PubMed ID: 33357843
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cancer vs. SARS-CoV-2 induced inflammation, overlapping functions, and pharmacological targeting.
    Amere Subbarao S
    Inflammopharmacology; 2021 Apr; 29(2):343-366. PubMed ID: 33723711
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 30.